GUANGZHOU, China – March 3, 2026 – CANWELL (Guangzhou) Biotech Co., Ltd. (“CANWELL Biotech”) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN1012, the company’s proprietary IFNα-biased TLR7 agonist, for the treatment of Soft Tissue Sarcoma (STS). This designation represents a significant milestone in CANWELL Biotech’s global strategic roadmap, validating the clinical potential of CAN1012 in addressing high unmet medical needs within the field of refractory oncology.

SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. As one of the world’s most prestigious healthcare investment symposium…

The 2025 European Society for Medical Oncology (ESMO) Annual Congress was held in Oct 17-19, Berlin, Germany. CanWell presented preliminary safety and efficacy data from its Phase 1b/2a clinical trial of CAN1012, a first-in-class IFNα-biased TLR7 agonist, in combination with toripalimab for advanced…

CanWell Pharma will present its latest development progress at the 16th World ADC held on Nov 3-6, 2025, in San Diego, CA. The presentation will be in the form of a poster. The poster will cover the newest research and development updates on company StarLinker dual/tri-payload ADCs, which had made s…

CanWell Pharma will present latest updates on company clinical development of CAN1012 at ESMO 2025 – Annual Meeting held on October 17-21, 2025 in Berlin. The presentation will be in a poster format during a poster session at the conference. The poster covers newest clinical study updates on t…